1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,048 | 0,081 | 12:46 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 18.12.25 | hVIVO PLC - Appointment of Non-Executive Director | - | RNS | ||
| 15.12.25 | hVIVO PLC - CEO & CFO Share Purchase | - | RNS | ||
| HVIVO Aktie jetzt für 0€ handeln | |||||
| 12.12.25 | Broker tips: Hvivo, Whitbread, IHG | 3 | Sharecast | ||
| 12.12.25 | Shore Capital hails improved US biotech funding environment for hVIVO | 1 | Sharecast | ||
| 27.11.25 | Hvivo client acquired by MSD in $9.2bn deal | 8 | Sharecast | ||
| 27.11.25 | hVIVO PLC - MSD to acquire Cidara | 24 | RNS | ||
| 20.11.25 | hVIVO PLC - >£5 million CRS contracts signed | - | RNS | ||
| 11.11.25 | hVIVO develops three new human challenge models for viral testing | 3 | Investing.com | ||
| 11.11.25 | hVIVO meldet erfolgreiche Entwicklung von drei neuen humanen Challenge-Modellen | 1 | Investing.com Deutsch | ||
| 11.11.25 | hVIVO PLC - Positive data from novel human challenge models | - | RNS | ||
| 03.11.25 | hVIVO PLC - Presentation at Jefferies Healthcare Conference | - | RNS | ||
| 23.09.25 | HVIVO Slides To Loss In H1 | - | RTTNews | ||
| 23.09.25 | hVIVO PLC - Interim results | - | RNS | ||
| 04.09.25 | hVIVO PLC - Notice of Results | 4 | RNS | ||
| 01.09.25 | hVIVO appoints Avacta Chair Shaun Chilton to lead board | 1 | Alliance News | ||
| 01.09.25 | hVIVO PLC - Appointment of Non-Executive Chair | - | RNS | ||
| 29.07.25 | hVIVO PLC - Proposed appointment of Chair | - | RNS | ||
| 27.01.25 | ILiAD Biotechnologies, LLC: ILiAD and hVIVO Sign LOI for Pivotal Phase 3 Trial of BPZE1 Pertussis Vaccine Following FDA Meeting | 325 | Business Wire | Trial anticipated for H2 2025 to evaluate most advanced next generation intranasal pertussis vaccine for whooping cough
ILiAD Biotechnologies, LLC, a biotech company developing BPZE1, the most... ► Artikel lesen |
18 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PLUS THERAPEUTICS | 0,286 | 0,00 % | PLUS THERAPEUTICS, INC. - 8-K, Current Report | ||
| ASENSUS SURGICAL | - | - | GlobalLogic, Asensus ink surgical robotics engineering collab | ||
| JD HEALTH INTERNATIONAL | 7,400 | +3,50 % | JD HEALTH, Peak Pharmaceutical Partner on Integrated Health Mgmt Solutions | ||
| LIFEWARD | 0,721 | 0,00 % | Oramed And Lifeward Reveal Strategic Deal | ||
| EKSO BIONICS | 8,220 | 0,00 % | Applied Digital Corporation: Applied Digital to Spin Out Cloud Business, Proposes Business Combination with EKSO to Launch ChronoScale | DALLAS, Dec. 29, 2025 (GLOBE NEWSWIRE) -- Applied Digital (NASDAQ: APLD), a designer, builder, and operator of high-performance, sustainably engineered data centers and colocation services for artificial... ► Artikel lesen | |
| IMUNON | 2,920 | -2,01 % | Imunon, Inc.: IMUNON Reports Third Quarter 2025 Financial Results and Provides Business Update | R&D Day showcased remarkable Investigator optimism, continued strengthening supportive data, and significant progress with Phase 3 OVATION 3 Study in pursuit of first frontline immunotherapy for advanced... ► Artikel lesen | |
| BIOCEPT | 7,200 | 0,00 % | GlaxoSmithKline Bioc: Gewinn im zweiten Quartal bei 5,9 Mio. EGP | ||
| ROCKWELL MEDICAL | 1,025 | -4,30 % | Why Is Rockwell Medical Gaining Tuesday? | ||
| VIRIDIAN THERAPEUTICS | 27,500 | -1,26 % | UBS stuft Viridian Therapeutics mit "Buy" ein - Kursziel impliziert 63 % Potenzial | ||
| SINTX TECHNOLOGIES | 3,650 | 0,00 % | SiNtx Technologies, Inc.: SINTX Technologies unterzeichnet Liefervertrag mit EVONIK zur Herstellung eines Siliziumnitrid-PEEK-Verbundwerkstoffes für KI-gestützte, 3D-gedruckte patientenspezifische Implantate | Ein Meilenstein, der die sofortige Produktion von maßgefertigten SiN/PEEK-Implantaten ermöglichtSALT LAKE CITY, Utah, Dec. 01, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) ("SINTX"... ► Artikel lesen | |
| AETHLON MEDICAL | 2,760 | 0,00 % | Morning Market Movers: Powell Max, Kaixin Holdings, Acadia Healthcare, Aethlon Medical See Big Swings | CANBERA (dpa-AFX) - At 7:25 a.m. ET on Wednesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| SAVARIA | 15,300 | -1,92 % | Savaria Corporation: Savaria to Host Investor Day | ||
| STAGEZERO LIFE SCIENCES | 0,028 | -100,00 % | StageZero Life Sciences Ltd.: StageZero Announces Partial Revocation of Failure to File Cease Trade Order and Proposed Financing | ||
| NEURONETICS | 1,776 | +7,51 % | Neuronetics Reports Third Quarter 2025 Financial and Operating Results and Announces CEO Transition Plan | Delivered $37.3 million total revenue in Q3 2025, representing 11% adjusted pro forma revenue growth versus Q3 2024 Generated Greenbrook clinic revenue of $21.8 million in Q3 2025, an increase of... ► Artikel lesen | |
| ARCH THERAPEUTICS | - | - | Arch Therapeutics, Inc. - 15-12G, Securities registration termination |
HVIVO PLC gehört der Branche Gesundheitswesen an. Der aktuelle Kurs liegt bei 0,054 Euro und damit -2,70 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu HVIVO PLC finden Sie auf Wallstreet Online.